Twist Bioscience Co. (NASDAQ:TWST) COO Sells $121,511.74 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,422 shares of the company’s stock in a transaction on Thursday, January 23rd. The shares were sold at an average price of $50.17, for a total value of $121,511.74. Following the sale, the chief operating officer now owns 272,044 shares of the company’s stock, valued at approximately $13,648,447.48. This trade represents a 0.88 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total value of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total value of $496,320.00.
• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total value of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $111,422.36.

Twist Bioscience Trading Down 0.7 %

Shares of Twist Bioscience stock opened at $51.86 on Wednesday. The stock has a 50 day moving average of $47.83 and a 200 day moving average of $46.36. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The firm has a market cap of $3.08 billion, a PE ratio of -14.41 and a beta of 1.85.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TWST. Thrivent Financial for Lutherans bought a new position in Twist Bioscience during the third quarter valued at approximately $43,992,000. State Street Corp raised its position in Twist Bioscience by 19.9% during the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares during the period. Wellington Management Group LLP raised its position in Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after purchasing an additional 521,272 shares during the period. Jennison Associates LLC raised its position in Twist Bioscience by 80.2% during the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after purchasing an additional 302,884 shares during the period. Finally, Driehaus Capital Management LLC raised its position in Twist Bioscience by 63.0% during the second quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock valued at $19,152,000 after purchasing an additional 150,260 shares during the period.

Wall Street Analyst Weigh In

TWST has been the subject of several recent research reports. Evercore ISI boosted their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Barclays cut their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Scotiabank boosted their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday, November 19th. Leerink Partners upped their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.